Role of IL-33 and IL-35 in the Pathogenesis of Rheumatoid Arthritis

1 McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet Lond Engl. 2017;389(10086):2328-37. Search in Google Scholar

2 Catrina AI, Joshua V, Klareskog L, Malmström V. Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev. 2016;269(1):162-74. Search in Google Scholar

3 Makuch, S.; Więcek, K.; Woźniak, M. The Immunomodulatory and Anti-Inflammatory Effect of Curcumin on Immune Cell Populations, Cytokines, and In Vivo Models of Rheumatoid Arthritis. Pharmaceuticals 2021;14(4):309. Search in Google Scholar

4 Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15 Search in Google Scholar

5 Noack, M.; Miossec, P. Selected cytokine pathways in rheumatoid arthritis. Semin. Immunopathol. 2017, 39, 365-83 Search in Google Scholar

6 Achudhan D, Liu SC, Lin YY, Huang CC, Tsai CH, Ko CY, Chiang IP, Kuo YH, Tang CH. Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:790925. Search in Google Scholar

7 Kumar, V.; Kanwar, J.R.; Verma, A.K. Rheumatoid arthritis: Basic pathophysiology and role of chitosan nanoparticles in therapy. In Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents; Singh, M.R., Singh, D., Kanwar, J.R., Chauhan, N.S., Eds.; Academic Press: Cambridge, MA, USA, 2020; pp. 481-507. ISBN 978-0-12-819666-3 Search in Google Scholar

8 Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. Search in Google Scholar

9 Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9-17. Search in Google Scholar

10 Liew FY, Girard J-P, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676-89. Search in Google Scholar

11 Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90. Search in Google Scholar

12 Baekkevold ES, Roussigné M, Yamanaka T, Johansen F-E, Jahnsen FL, Amalric F, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163(1):69-79. Search in Google Scholar

13 Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem. 2011;286(22):20078-86. Search in Google Scholar

14 Carriere V, Roussel L, Ortega N, Lacorre D-A, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104(1):282-7. Search in Google Scholar

15 Travers J, Rochman M, Miracle CE, Habel JE, Brusilovsky M, Caldwell JM, et al. Chromatin regulates IL-33 release and extracellular cytokine activity. Nat Commun. 2018;9(1):3244. Search in Google Scholar

16 Roussel L, Erard M, Cayrol C, Girard J-P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008;9(10):1006-12. Search in Google Scholar

17 Cayrol C, Girard J-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31-7. Search in Google Scholar

18 Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281(1):154-68. Search in Google Scholar

19 Cayrol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021-6. Search in Google Scholar

20 Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84-98. Search in Google Scholar

21 Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J-P, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A. 2012;109(5):1673-8. Search in Google Scholar

22 Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PloS One. 2008;3(10):e3331. Search in Google Scholar

23 Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol Baltim Md 1950. 2009;183(8):5094-103. Search in Google Scholar

24 Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16-26. Search in Google Scholar

25 Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998;95(12):6930-5. Search in Google Scholar

26 Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-8. Search in Google Scholar

27 Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367-70. Search in Google Scholar

28 Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol Baltim Md 1950. 2009;183(10):6469-77. Search in Google Scholar

29 Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol Baltim Md 1950. 1998;161(9):4866-74. Search in Google Scholar

30 Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484-90. Search in Google Scholar

31 Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol Baltim Md 1950. 2008;181(9):5981-9. Search in Google Scholar

32 Smithgall MD, Comeau MR, Yoon B-RP, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019-30. Search in Google Scholar

33 Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 2012;335(6071):984-9. Search in Google Scholar

34 Peine M, Marek RM, Löhning M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. Trends Immunol. 2016;37(5):321-33. Search in Google Scholar

35 Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol Baltim Md 1950. 2008;181(7):4780-90. Search in Google Scholar

36 Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113(7):1526-34. Search in Google Scholar

37 Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D. Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology. 2016;221(3):412-7. Search in Google Scholar

38 Baumann C, Bonilla WV, Fröhlich A, Helmstetter C, Peine M, Hegazy AN, et al. T-bet- and STAT4- dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci U S A. 2015;112(13):4056-61. Search in Google Scholar

39 Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318(1):83-7. Search in Google Scholar

40 Liu X, Hammel M, He Y, Tainer JA, Jeng U-S, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A. 2013;110(37):14918-23. Search in Google Scholar

41 Molofsky AB, Savage AK, Locksley RM. Interleukin- 33 in Tissue Homeostasis, Injury, and Inflammation. Immunity. 2015;42(6):1005-19. Search in Google Scholar

42 Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107(5):650-8. Search in Google Scholar

43 Duan L, Chen J, Zhang H, Yang H, Zhu P, Xiong A, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice. Mol Med Camb Mass. 2012;18:753-61. Search in Google Scholar

44 Pavlovic S, Petrovic I, Jovicic N, Ljujic B, Miletic Kovacevic M, Arsenijevic N, et al. IL-33 Prevents MLDSTZ Induction of Diabetes and Attenuate Insulitis in Prediabetic NOD Mice. Front Immunol. 2018;9:2646. Search in Google Scholar

45 Macedo RBV, Kakehasi AM, Melo de Andrade MV. IL33 in rheumatoid arthritis: potential contribution to pathogenesis. Rev Bras Reumatol. 2016;56(5):451-7 Search in Google Scholar

46 Dong Y, Zhong J, Dong L. IL-33 in Rheumatic Diseases. Front Med (Lausanne). 2021 ;8:739489 Search in Google Scholar

47 Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin- 1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-15. Search in Google Scholar

48 Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 2010;37(1):18-25. Search in Google Scholar

49 Aliaa M. Abd El-Aziz Faraga , Nagat M. El-Gazzarb , Marwa A.Abo El Hawab , Mohamed A.Saad Attia. Study of interleukin 33 in rheumatoid arthritis versus osteoarthritis patients. Egyptian Rheumatology & Rehabilitation 2017;44:159-63. Search in Google Scholar

50 Salama AA, Mahmoud AB, Al-Sharaki DR, Gomah AF. Role of interleukin-33 in rheumatoid arthritis patients from Menoufia University Hospitals. Menoufia Med J 2017;30:952-7 Search in Google Scholar

51 Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol Baltim Md 1950. 2004;173(1):145-50. Search in Google Scholar

52 Xu D, Jiang H-R, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105(31):10913-8. Search in Google Scholar

53 Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin- 33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60(3):738-49. Search in Google Scholar

54 Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, et al. In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. J Immunol Baltim Md 1950. 2016;197(5):1708-19. Search in Google Scholar

55 Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther. 2013;15(1):R13. Search in Google Scholar

56 Athari SK, Poirier E, Biton J, Semerano L, Hervé R, Raffaillac A, et al. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis Res Ther. 2016;18(1):143. Search in Google Scholar

57 Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-α dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29(4):530-40. Search in Google Scholar

58 Hong Y-S, Moon S-J, Joo Y-B, Jeon C-H, Cho M-L, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL- 33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1132-9. Search in Google Scholar

59 Tang S, Huang H, Hu F, Zhou W, Guo J, Jiang H, et al. Increased IL-33 in Synovial Fluid and Paired Serum Is Associated with Disease Activity and Autoantibodies in Rheumatoid Arthritis. Clin Dev Immunol. 2013;2013:985301. Search in Google Scholar

60 Devergne O, Birkenbach M, Kieff E. Epstein-Barr virusinduced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A. 1997;94(22):12041-6. Search in Google Scholar

61 Xin PL, Jie LF, Cheng Q, Bin DY, Dan CW. Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis. Front Pharmacol. 2021;12:655114. Search in Google Scholar

62 Zhang J, Zhang Y, Wang Q, Li C, Deng H, Si C, et al. Interleukin-35 in immune-related diseases: protection or destruction. Immunology. 2019;157(1):13-20. Search in Google Scholar

63 Belladonna ML, Grohmann U. Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnol Genet Eng Rev. 2013;29:149-74. Search in Google Scholar

64 Zhang FF, Liu S, John EM, Must A, Demark-Wahnefried W. Diet quality of cancer survivors and noncancer individuals: Results from a national survey. Cancer. 2015;121(23):4212-21. Search in Google Scholar

65 Li X, Shao Y, Sha X, Fang P, Kuo Y-M, Andrews AJ, et al. IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14). Arterioscler Thromb Vasc Biol. 2018;38(3):599-609. Search in Google Scholar

66 Dambuza IM, He C, Choi JK, Yu C-R, Wang R, Mattapallil MJ, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. Nat Commun. 2017;8(1):719. Search in Google Scholar

67 Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014;69(1):87-93. Search in Google Scholar

68 Li Y, Jie Y, Wang X, Lu J. Serum IL-35 is decreased in overweight patients with rheumatoid arthritis: its correlation with Th1/Th2/Th17-related cytokines. BMC Immunol. 2021;22(1):42. Search in Google Scholar

69 Niedbala W, Wei X-Q, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021-9. Search in Google Scholar

70 Li Y, Yao L, Liu S, Wu J, Xia L, Shen H, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. J Investig Med Off Publ Am Fed Clin Res. 2019;67(3):707-10. Search in Google Scholar

71 Wang D, Lei L. Interleukin-35 regulates the balance of Th17 and Treg responses during the pathogenesis of connective tissue diseases. Int J Rheum Dis. 2021;24(1):21-7. Search in Google Scholar

72 Xie Q, Xu W-D, Pan M, Lan Y-Y, Liu X-Y, Su L-C, et al. Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis. Int Immunopharmacol. 2021;90:107231. Search in Google Scholar

73 Wang X, Zhong W. Isorhamnetin attenuates collageninduced arthritis via modulating cytokines and oxidative stress in mice. Int J Clin Exp Med. 2015;8(9):16536-42. Search in Google Scholar

74 Li Y, Li D, Li Y, Wu S, Jiang S, Lin T, et al. Interleukin- 35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27(4):1537-46. Search in Google Scholar

75 Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand. Cent-Eur J Immunol. 2018;43(2):148-54. Search in Google Scholar